Literature DB >> 22332064

Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects.

Evis Sala1, Masako Y Kataoka, Andrew N Priest, Andrew B Gill, Mary A McLean, Ilse Joubert, Martin J Graves, Robin A F Crawford, Mercedes Jimenez-Linan, Helena M Earl, Charlotte Hodgkin, John R Griffiths, David J Lomas, James D Brenton.   

Abstract

PURPOSE: To investigate the role of multiparametric magnetic resonance (MR) imaging in the evaluation of response to platinum-based neoadjuvant chemotherapy in advanced ovarian cancer and to compare imaging parameters between primary ovarian mass and metastatic disease.
MATERIALS AND METHODS: Evaluable patients suspected of having advanced ovarian carcinoma were enrolled in a prospective protocol-driven study. Research ethics committee approval and written informed consent were obtained. Multiparametric MR imaging (diffusion-weighted MR imaging, dynamic contrast material-enhanced [DCE] MR imaging, and hydrogen 1 MR spectroscopy) was performed with a 3.0-T wholebody MR imaging system. Three marker lesions-primary ovarian mass, omental cake, and peritoneal deposit-were outlined by a radiologist on apparent diffusion coefficient (ADC) and vascular signal fraction (VSF) maps and on DCE MR images. Comparisons of mean ADC, mean VSF, DCE MR imaging parameters, and choline concentration between responders and nonresponders were based on Response Evaluation Criteria in Solid Tumors and CA-125 criteria.
RESULTS: Twenty-two patients were evaluable. The mean ADC for peritoneal metastases was lower than that for ovarian (P = .015) and omental (P = .006) sites. There were no differences in pretreatment DCE MR imaging parameters between tumor sites. After treatment, responders showed a significantly larger increase in ADC (P = .021) and fractional volume of the extravascular extracellular space (v(e)) (P = .025) of ovarian lesions compared with nonresponders, but there was no change in ADC at other sites. Pre- and posttreatment values of choline concentration of ovarian lesions were lower in responders (P = .025) than in nonresponders (P = .010).
CONCLUSION: The significant differences in baseline ADCs among primary ovarian cancer, omental cake, and peritoneal deposits indicate that diffusivity profiles may be tumor-site dependent, suggesting biologic heterogeneity of disease. ADC and v(e) parameters correlated with the cytotoxic effects of platinum-based therapy and may be useful response markers, while choline concentration predicted but did not reflect response. © RSNA, 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22332064     DOI: 10.1148/radiol.11110175

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  39 in total

1.  Effect of color visualization and display hardware on the visual assessment of pseudocolor medical images.

Authors:  Silvina Zabala-Travers; Mina Choi; Wei-Chung Cheng; Aldo Badano
Journal:  Med Phys       Date:  2015-06       Impact factor: 4.071

2.  Do DWI and quantitative DCE perfusion MR have a prognostic value in high-grade serous ovarian cancer?

Authors:  Francesca De Piano; Valentina Buscarino; Dulia Maresca; Patrick Maisonneuve; Giovanni Aletti; Roberta Lazzari; Andrea Vavassori; Massimo Bellomi; Stefania Rizzo
Journal:  Radiol Med       Date:  2019-08-31       Impact factor: 3.469

3.  Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic adenocarcinoma treated with chemotherapy.

Authors:  Yoshihiko Fukukura; Yuichi Kumagae; Ryutaro Higashi; Hiroto Hakamada; Koji Takumi; Kosei Maemura; Michiyo Higashi; Kiyohisa Kamimura; Masanori Nakajo; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

4.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

Review 5.  Molecular Imaging of Ovarian Cancer.

Authors:  Sai Kiran Sharma; Brandon Nemieboka; Evis Sala; Jason S Lewis; Brian M Zeglis
Journal:  J Nucl Med       Date:  2016-04-28       Impact factor: 10.057

Review 6.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

7.  Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma.

Authors:  Mercedes Espada; Jose R Garcia-Flores; Mar Jimenez; Elena Alvarez-Moreno; Mar De Haro; Lucia Gonzalez-Cortijo; Gines Hernandez-Cortes; Vicente Martinez-Vega; Ricardo Sainz De La Cuesta
Journal:  Eur Radiol       Date:  2013-04-19       Impact factor: 5.315

8.  Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study.

Authors:  Feng Zhang; Thomas Le; Xia Wu; Han Wang; Tong Zhang; Yanfeng Meng; Baojie Wei; Stephanie S Soriano; Patrick Willis; Orpheus Kolokythas; Xiaoming Yang
Journal:  Radiology       Date:  2013-11-08       Impact factor: 11.105

9.  Diffusion-weighted MRI monitoring of pancreatic cancer response to radiofrequency heat-enhanced intratumor chemotherapy.

Authors:  Tong Zhang; Feng Zhang; Yanfeng Meng; Han Wang; Thomas Le; Baojie Wei; Donghoon Lee; Patrick Willis; Baozhong Shen; Xiaoming Yang
Journal:  NMR Biomed       Date:  2013-09-04       Impact factor: 4.044

Review 10.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.